Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-Blind, Double Dummy, Comparative, Multicenter Study to Assess the Incidence of Hemolysis, Safety, and Efficacy of Tafenoquine (SB-252263, WR238605) Versus Primaquine in the Treatment of Subjects With Plasmodium Vivax Malaria

Trial Profile

A Randomized, Double-Blind, Double Dummy, Comparative, Multicenter Study to Assess the Incidence of Hemolysis, Safety, and Efficacy of Tafenoquine (SB-252263, WR238605) Versus Primaquine in the Treatment of Subjects With Plasmodium Vivax Malaria

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 16 Jan 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tafenoquine (Primary) ; Chloroquine; Primaquine
  • Indications Malaria
  • Focus Registrational; Therapeutic Use
  • Acronyms GATHER
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 16 Jan 2019 According to a GlaxoSmithKline media release, results from DETECTIVE and GATHER studies published in The New England Journal of Medicine.
    • 21 Sep 2018 According to a GlaxoSmithKline media release,Kozenis (tafenoquine) approved by the Australian Therapeutic Goods Administration for the radical cure of P. vivax malaria.Thia approval is based on the data from DETECTIVE and GATHER study.
    • 10 Sep 2018 Results published in the Antimicrobial Agents and Chemotherapy
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top